GLP-1 Medication Safety - Advanced Lab Panel
The GLP-1 Medication Safety Advanced Lab Panel supports people using semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound, or compounded GLP-1 medications. It evaluates kidney filtration, urine health, liver and bile-flow markers, pancreatic enzymes, blood sugar, insulin, cholesterol, ApoB, Lp(a), inflammation, iron status, magnesium, vitamin D, B12, folate, thyroid markers, omega fatty acids, and protein nutrition with prealbumin.
- $2,830.21
- $564
- Save: 80.07%
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Microalbumin Random Urine with Creatinine
Creatinine, Random Urine
Microalbumin
Microalbumin/Creatinine
Amylase
Apolipoprotein B
Also known as: Bilirubin Fractionated
Bilirubin, Direct
Bilirubin, Indirect
Bilirubin, Total
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Absolute Band Neutrophils (Only Reported If Detected)
Absolute Basophils
Absolute Blasts (Only Reported If Detected)
Absolute Eosinophils
Absolute Lymphocytes
Absolute Metamyelocytes (Only Reported If Detected)
Absolute Monocytes
Absolute Myelocytes (Only Reported If Detected)
Absolute Neutrophils
Absolute Nucleated Rbc (Only Reported If Detected)
Absolute Promyelocytes (Only Reported If Detected)
Band Neutrophils (Only Reported If Detected)
Basophils
Blasts (Only Reported If Detected)
Eosinophils
Hematocrit
Hemoglobin
Lymphocytes
MCH
MCHC
MCV
Metamyelocytes (Only Reported If Detected)
Monocytes
MPV
Myelocytes (Only Reported If Detected)
Neutrophils
Nucleated Rbc (Only Reported If Detected)
Platelet Count
Promyelocytes (Only Reported If Detected)
RDW
Reactive Lymphocytes (Only Reported If Detected)
Red Blood Cell Count
White Blood Cell Count
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Albumin
Albumin/Globulin Ratio
Alkaline Phosphatase
Alt
AST
Bilirubin, Total
Bun/Creatinine Ratio
Calcium
Carbon Dioxide
Chloride
Creatinine
Egfr African American
Egfr Non-Afr. American
GFR-AFRICAN AMERICAN
GFR-NON AFRICAN AMERICAN
Globulin
Glucose
Potassium
Protein, Total
Sodium
Urea Nitrogen (Bun)
Also known as: CK (Total), CPK, CPK (Total), Creatine Kinase CK Total, Creatine Phosphokinase (CPK), Total CK
Creatine Kinase, Total
CYSTATIN C
eGFR
Ferritin
Also known as: Gamma Glutamyl Transferase GGT, Gamma-Glutamyl Transferase, Gamma-Glutamyl Transpeptidase, Gamma-GT, GGTP, GTP
Ggt
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
HEMOGLOBIN A1C
Also known as: C-Reactive Protein, Cardio CRP, Cardio hs-CRP, CRP, High Sensitivity CRP, High-sensitivity C-reactive Protein, High-sensitivity CRP, Highly Sensitive CRP, hsCRP, Ultra-sensitive CRP
Hs Crp
Also known as: Insulin (fasting)
Insulin
Also known as: Iron and TIBC, Iron and Total Iron Binding Capacity TIBC, TIBC
% Saturation
Iron Binding Capacity
Iron, Total
Also known as: LPS
Lipase
Also known as: Cholesterol, HDL,Fasting Lipids,Cholesterol, LDL, Fasting Lipids, Lipid Panel (fasting), Lipid Profile (fasting), Lipids
Chol/HDLC Ratio
Cholesterol, Total
HDL Cholesterol
LDL-Cholesterol
Non HDL Cholesterol
Triglycerides
Also known as: Lipoprotein A, Lp (a), Lp(a)
Lipoprotein (A)
Magnesium
ARACHIDONIC ACID
ARACHIDONIC ACID/EPA
DHA
DPA
EPA
EPA+DPA+DHA
LINOLEIC ACID
OMEGA-3 TOTAL
OMEGA-6 TOTAL
OMEGA-6/OMEGA-3 RATIO
Also known as: Thyroxine Binding Prealbumin, Thyroxine-binding Prealbumin, Transthyretin
Prealbumin
Vitamin D, 25-Oh, D2
Vitamin D, 25-Oh, D3
Vitamin D, 25-Oh, Total
Also known as: Free T4, FT4, T4 Free
T4, Free
Also known as: Thyroid Stimulating Hormone Test, Thyrotropin Test
TSH
Also known as: UA, Complete, Urinalysis UA Complete, Urine Analysis, Complete
Amorphous Sediment (Only Reported If Detected)
Appearance
Bacteria
Bilirubin
Calcium Oxalate Crystals (Only Reported If Detected)
Casts (Only Reported If Detected)
Color
Crystals (Only Reported If Detected)
Glucose
Granular Cast (Only Reported If Detected)
Hyaline Cast
Ketones
Leukocyte Esterase
Nitrite
Occult Blood
Ph
Protein
Rbc
Reducing Substances (Only Reported If Detected)
Renal Epithelial Cells (Only Reported If Detected)
Specific Gravity
Squamous Epithelial Cells
Transitional Epithelial (Only Reported If Detected)
Triple Phosphate Crystals (Only Reported If Detected)
Uric Acid Crystals (Only Reported If Detected)
WBC
YEAST (Only Reported If Detected)
Also known as: Cobalamin, Folic Acid, Vitamin B 12, Vitamin B 12 and Folic Acid, Vitamin B12 Cobalamin and Folate Panel Serum, Vitamin B12/Folic Acid
Folate, Serum
Vitamin B12
The GLP-1 Medication Safety - Advanced Lab Panel panel contains 25 tests with 127 biomarkers .
Overview
The GLP-1 Medication Safety Advanced Lab Panel is designed for people using GLP-1 or GLP-1/GIP medications such as semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound, or compounded GLP-1 medications who want a deeper lab-based review of safety, metabolic response, nutrition status, and weight-loss wellness.
GLP-1 medications can support weight management and blood sugar improvement for appropriate patients, but safety monitoring may be useful because these medications may overlap with hydration status, kidney function, gastrointestinal symptoms, pancreatic enzyme concerns, gallbladder or bile-flow concerns, nutrition status, thyroid review, lipid changes, and metabolic improvement.
FDA prescribing information for semaglutide and tirzepatide includes warnings related to acute kidney injury due to volume depletion, acute gallbladder disease, and acute pancreatitis, particularly when symptoms such as persistent nausea, vomiting, diarrhea, dehydration, or abdominal pain are present.
This panel does not prove that a GLP-1 medication is safe or unsafe by itself. Results should be interpreted with a licensed healthcare provider and reviewed alongside the medication used, dose, duration, dose changes, symptoms, weight-loss rate, hydration, diet, other medications, and health history.
Why Order This Panel?
The GLP-1 Medication Safety Advanced Lab Panel may be helpful for customers who want more than a basic GLP-1 monitoring panel. It includes the key organ function and metabolic markers commonly reviewed during GLP-1 use, while adding advanced cardiometabolic, nutrition, omega fatty acid, thyroid, and protein-status markers.
This panel may help provide insight into:
- Kidney filtration and urine health
- Hydration-related urine findings
- Liver function, bile flow, and bilirubin patterns
- Pancreatic enzyme activity
- Blood sugar and insulin patterns
- Cholesterol, triglycerides, ApoB, and Lipoprotein(a)
- Inflammation and cardiometabolic risk context
- Iron storage and iron availability
- Blood count and anemia-related patterns
- Magnesium, vitamin D, vitamin B12, and folate status
- Thyroid function
- Omega fatty acid status
- Protein nutrition and reduced-intake patterns during weight loss
This Panel May Be Helpful For People Using
- Semaglutide
- Tirzepatide
- Ozempic
- Wegovy
- Mounjaro
- Zepbound
- Compounded GLP-1 medications
- GLP-1 medications with metformin, insulin, sulfonylureas, statins, or blood pressure medications
- GLP-1 medications with calorie restriction, reduced appetite, rapid weight loss, or high-protein nutrition plans
- GLP-1 medications with nausea, vomiting, diarrhea, constipation, abdominal discomfort, fatigue, reduced intake, or dehydration concerns
Common Symptoms or Situations This Panel May Help Evaluate
This panel may be useful for people with or concerned about:
- Nausea, vomiting, diarrhea, constipation, or reduced fluid intake
- Dehydration or kidney function concerns
- Abdominal discomfort or pancreatic enzyme concerns
- Gallbladder or bile-flow concerns
- Rapid weight loss
- Reduced appetite and reduced protein intake
- Fatigue or low energy
- Blood sugar improvement or hypoglycemia risk when combined with insulin or sulfonylureas
- High cholesterol, triglycerides, ApoB, or inherited cardiovascular risk
- Iron, vitamin D, B12, folate, magnesium, omega fatty acid, or protein nutrition concerns
- Desire for a deeper baseline before or during GLP-1 therapy
Tirzepatide labeling notes that acute kidney injury may occur due to volume depletion and recommends monitoring renal function in patients reporting adverse reactions that could lead to volume depletion.
What This Panel Helps Evaluate
This panel helps evaluate selected biomarkers related to:
- GLP-1 medication safety monitoring
- Kidney filtration
- Urine albumin and urinalysis patterns
- Liver function and bile flow
- Bilirubin processing
- Pancreatic enzyme activity
- Blood sugar and insulin response
- Cholesterol, triglycerides, ApoB, and Lp(a)
- Low-grade inflammation
- Blood count patterns
- Iron status
- Magnesium status
- Vitamin D status
- Vitamin B12 and folate status
- Thyroid screening
- Omega fatty acid balance
- Protein nutrition during weight loss
Tests Included and Why They Matter
Kidney Function, Hydration & Urine Health
GLP-1 medications can reduce appetite and may cause nausea, vomiting, diarrhea, constipation, or reduced fluid intake in some people. When fluid intake drops or gastrointestinal symptoms persist, kidney stress can become more important to monitor. This group helps evaluate filtration, urine findings, and early kidney stress patterns.
Comprehensive Metabolic Panel, CMP
The CMP evaluates glucose, kidney function, liver function, electrolytes, calcium, albumin, total protein, and other metabolic markers.
This test is included because GLP-1 users may benefit from a broad safety baseline that includes kidney markers, liver enzymes, electrolytes, glucose, calcium, albumin, and protein status. The CMP helps provide important context when appetite, hydration, weight loss, medication changes, or gastrointestinal symptoms are present.
Cystatin C with eGFR
Cystatin C with eGFR provides an additional way to evaluate kidney filtration.
This test is included because cystatin C can add kidney function context beyond creatinine alone. It may be useful when reviewing medication safety, dehydration risk, muscle mass changes, weight loss, or kidney function concerns during GLP-1 therapy.
Albumin, Random Urine with Creatinine
This urine test evaluates albumin relative to creatinine.
It is included because urine albumin may provide early kidney and vascular stress context. This can be especially relevant for people using GLP-1 medications for diabetes, prediabetes, metabolic syndrome, high blood pressure, or kidney-risk monitoring.
Urinalysis, UA, Complete
A complete urinalysis evaluates urine markers such as protein, blood, glucose, ketones, specific gravity, pH, and other findings.
This test is included because urine findings may provide practical safety context for hydration, kidney health, glucose handling, ketone production, protein, blood, and urinary abnormalities. It may be especially useful if a customer has reduced intake, increased ketones from low-carbohydrate eating, dehydration concerns, or kidney-related symptoms.
Liver Function, Bile Flow & Gallbladder Context
GLP-1 medication use and weight loss may overlap with liver, bile-flow, and gallbladder-related concerns. This group helps evaluate liver enzyme context, bile-flow patterns, and bilirubin processing.
Gamma Glutamyl Transferase, GGT
GGT is a liver and bile duct enzyme.
This test is included because it may provide additional context for bile flow, liver stress, fatty liver patterns, alcohol exposure, medication use, supplement use, and metabolic liver health. In a GLP-1 panel, GGT adds useful bile-flow and liver-processing context beyond standard CMP liver enzymes alone.
Bilirubin, Fractionated
Bilirubin, Fractionated measures total, direct, and indirect bilirubin.
This test is included because bilirubin patterns may provide more detailed context for liver processing, bile flow, red blood cell breakdown, and bilirubin metabolism. Fractionated bilirubin is useful in a GLP-1 safety panel because bile-flow and gallbladder-related concerns may require careful provider-guided interpretation.
Pancreatic Enzyme Support
GLP-1 prescribing information includes warnings related to acute pancreatitis. These enzymes are not used to prove a medication is safe, but they may provide pancreas-related context when symptoms or provider concerns are present. Zepbound prescribing information states that acute pancreatitis has been observed with GLP-1 receptor agonists or tirzepatide and recommends discontinuation if pancreatitis is suspected.
Lipase
Lipase is an enzyme related to pancreatic function and fat digestion.
This test is included because lipase may provide pancreas-related context when people using GLP-1 medications have abdominal symptoms or provider concerns. Lipase is often more pancreas-specific than amylase and is a strong fit for a GLP-1 medication safety panel.
Amylase
Amylase is an enzyme involved in carbohydrate digestion and is produced by the pancreas and salivary glands.
This test is included because it may provide additional pancreatic enzyme context when reviewed with lipase, symptoms, medication history, and provider guidance. Amylase should not be interpreted alone, but it can add value when abdominal symptoms or pancreatic concerns are part of the clinical picture.
Blood Sugar, Insulin & Metabolic Response
GLP-1 medications are commonly used for blood sugar control, weight management, and metabolic health. This group helps evaluate glucose trends, insulin response, and cardiometabolic changes during therapy.
Hemoglobin A1c
Hemoglobin A1c measures average blood sugar over approximately the past two to three months.
This test is included because GLP-1 medications are often used to improve blood sugar and metabolic health. A1c can help track longer-term glucose trends, diabetes or prediabetes risk, and response to lifestyle and medication changes.
Insulin
Insulin helps move glucose from the bloodstream into cells.
This test is included because insulin may provide additional context for insulin resistance, metabolic flexibility, appetite and weight-loss response, and blood sugar regulation. It may be useful when evaluating how the body’s metabolic signals are changing during GLP-1 therapy.
Lipids, Cardiovascular Risk & Omega Fatty Acids
Weight loss, dietary changes, improved insulin sensitivity, and medication use can affect cholesterol and triglyceride patterns. This group helps evaluate standard lipids plus advanced cardiovascular markers.
Lipid Panel
The Lipid Panel evaluates total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
This test is included because weight loss, dietary changes, metabolic improvement, and medications can influence lipid patterns. It provides core cardiovascular and metabolic context during GLP-1 treatment.
Apolipoprotein B
Apolipoprotein B, or ApoB, reflects the number of atherogenic cholesterol-carrying particles.
This test is included because ApoB may provide deeper cardiometabolic risk context than LDL cholesterol alone, especially in people with insulin resistance, metabolic syndrome, diabetes, high triglycerides, or weight-loss-related lipid changes.
Lipoprotein(a)
Lipoprotein(a), or Lp(a), is an inherited cholesterol-related marker.
This test is included because Lp(a) may provide additional cardiovascular risk context that is not captured by a standard Lipid Panel. It is often measured once or periodically depending on provider guidance and family history.
OMEGACHECK™
OMEGACHECK™ evaluates omega fatty acid status.
This test is included because omega-3 and omega-6 fatty acid patterns may provide context for inflammation balance, cardiovascular wellness, nutrition quality, and supplement use during weight-loss therapy.
Inflammation, Blood Health & Iron Status
Weight loss, metabolic changes, nutrition intake, and inflammation can affect energy, recovery, and overall wellness. This group helps evaluate blood count patterns, iron status, and low-grade inflammation.
CBC, includes Differential and Platelets
The CBC evaluates red blood cells, white blood cells, hemoglobin, hematocrit, platelets, and white blood cell types.
This test is included because GLP-1 users may benefit from a blood count baseline when evaluating fatigue, low energy, inflammation, infection clues, anemia-related patterns, or general wellness.
Ferritin
Ferritin measures stored iron.
This test is included because ferritin may provide context for iron storage, anemia-related patterns, inflammation, liver/metabolic patterns, and fatigue. Ferritin can be low with iron deficiency or elevated with inflammation, so it should be interpreted with iron/TIBC, CBC, hs-CRP, symptoms, and health history.
Iron and Total Iron Binding Capacity, TIBC
Iron and TIBC help evaluate circulating iron and iron transport capacity.
This test is included because iron deficiency, iron overload, or abnormal iron availability may contribute to fatigue, weakness, poor stamina, and anemia-related concerns. It adds useful context when appetite and dietary intake change during GLP-1 therapy.
hs-CRP
High-sensitivity C-reactive protein is a marker of low-grade inflammation.
This test is included because inflammation may provide useful context for metabolic health, cardiometabolic risk, ferritin interpretation, liver/metabolic patterns, and general wellness during weight loss.
Nutrition, Protein & Micronutrient Support During Weight Loss
Reduced appetite, smaller meals, nausea, dietary changes, and rapid weight loss may affect nutrient and protein intake. This group helps evaluate nutrients commonly reviewed when fatigue, reduced intake, muscle symptoms, bone health, or poor recovery are concerns.
Prealbumin
Prealbumin is a protein nutrition marker.
This test is included because GLP-1 users may experience reduced appetite and lower total food intake. Prealbumin may provide helpful context for protein nutrition, under-fueling, low energy availability, or inadequate intake during weight loss.
Magnesium
Magnesium supports muscle function, nerve signaling, blood pressure regulation, glucose metabolism, sleep, and energy production.
This test is included because magnesium status may provide context for muscle cramps, fatigue, blood pressure, metabolic health, constipation, sleep, and supplement safety during GLP-1 therapy.
QuestAssureD™ 25-Hydroxyvitamin D, D2, D3, LC/MS/MS
Vitamin D testing measures vitamin D status.
This test is included because vitamin D may be relevant to bone health, immune function, muscle symptoms, inflammation, calcium balance, and general wellness. It is especially useful when appetite, dietary intake, or weight status changes.
Vitamin B12 and Folate Panel, Serum
This panel measures vitamin B12 and folate.
These nutrients support red blood cell production, nerve function, DNA synthesis, methylation, and general wellness. This test is included because B12 and folate status may be relevant to fatigue, neurologic symptoms, restricted intake, metformin use, acid-reducing medications, and reduced food intake during GLP-1 therapy.
Thyroid Function & Weight-Loss Wellness Context
Thyroid markers do not determine whether a GLP-1 medication is safe by themselves, but they may provide useful context when fatigue, weight changes, metabolism, or baseline wellness are part of the discussion.
TSH
TSH, or thyroid-stimulating hormone, is a key thyroid screening marker.
This test is included because thyroid function may influence energy, metabolism, weight, bowel habits, mood, and overall wellness. It provides useful baseline context in people using medications for weight management or metabolic health.
T4, Free
Free T4 measures the available form of thyroxine, a thyroid hormone.
This test is included because Free T4 adds thyroid hormone production context when reviewed with TSH, symptoms, and provider guidance.
Related Biomarker Patterns This Panel May Help Identify
This panel may help identify or rule out lab patterns related to:
- Kidney filtration changes
- Urine albumin or urinalysis abnormalities
- Hydration-related urine patterns
- Liver enzyme or bile-flow changes
- Bilirubin pattern changes
- Pancreatic enzyme elevation
- Blood sugar improvement or imbalance
- Insulin resistance patterns
- Cholesterol, ApoB, or Lp(a)-related cardiovascular risk
- Omega fatty acid status
- Low-grade inflammation
- Anemia-related patterns
- Iron deficiency or abnormal iron availability
- Protein nutrition status
- Magnesium status
- Vitamin D status
- Vitamin B12 and folate status
- Thyroid marker patterns
- General GLP-1 medication safety concerns
Professional Safety and Interpretation Notice
This panel is designed to support GLP-1 medication safety review. It does not prove that a GLP-1 medication is safe or unsafe by itself. Results should be interpreted with a licensed healthcare provider and reviewed alongside medication type, dose, duration, symptoms, hydration, diet, weight-loss rate, medical conditions, other medications, and health goals.
Do not stop or change any prescribed medication without guidance from your healthcare provider.
Additional Panels to Consider
Customers interested in the GLP-1 Medication Safety Advanced Lab Panel may also consider:
- GLP-1 Medication Safety Essential Lab Panel
- Medication Safety Lab Panel
- Medication & Supplement Safety Lab Panel
- Supplement Safety Lab Panel
- Kidney, Liver & Detox Support Lab Panel
- Prediabetes & Insulin Resistance Lab Panel
- Heart Health & Cholesterol Lab Panel
- Vitamin, Mineral & Nutrient Deficiency Lab Panel
- Athletic Performance & Recovery Lab Panel
- Hormone Therapy Safety Lab Panel
- Thyroid & Metabolism Lab Panel
How to Prepare for This Panel
Preparation may vary depending on the specific tests included and instructions provided with your order. In general:
- Fasting may be recommended because glucose, insulin, and lipid markers are included.
- Bring or keep a list of medications, including GLP-1 medication name, dose, start date, dose changes, and any other diabetes, blood pressure, cholesterol, or weight-loss medications.
- Note symptoms such as nausea, vomiting, diarrhea, constipation, abdominal pain, dehydration, dizziness, fatigue, low appetite, or changes in urination.
- Drink water normally unless instructed otherwise.
- Do not overhydrate before urine testing.
- Continue medications unless your healthcare provider tells you otherwise.
- Follow all lab collection instructions provided with your order.
What Happens After You Receive Your Results?
After your results are available, your biomarkers can help organize GLP-1 safety findings into areas such as kidney filtration, urine health, hydration context, liver function, bile flow, pancreatic enzymes, blood sugar, insulin, lipids, ApoB, Lp(a), inflammation, iron status, magnesium, vitamin D, B12, folate, thyroid markers, omega fatty acids, and protein nutrition.
During the physician consultation, you can discuss whether your results suggest the need for follow-up testing, medication review, hydration changes, nutrition support, dose discussion, or additional monitoring based on your health history and current GLP-1 use.
Frequently Asked Questions
What is the GLP-1 Medication Safety Advanced Lab Panel?
The GLP-1 Medication Safety Advanced Lab Panel is a blood and urine panel that evaluates selected biomarkers related to kidney function, liver function, pancreatic enzymes, blood sugar, insulin, cholesterol, inflammation, iron status, magnesium, vitamin D, B12, folate, thyroid markers, omega fatty acids, protein nutrition, and urine health for people using GLP-1 medications.
Who may benefit from this panel?
This panel may be useful for people taking semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound, or compounded GLP-1 medications who want deeper safety, nutrition, and metabolic monitoring.
Why are kidney markers included?
Kidney markers are included because nausea, vomiting, diarrhea, dehydration, or reduced fluid intake may affect kidney safety during GLP-1 therapy. FDA labeling for tirzepatide includes monitoring renal function in patients reporting adverse reactions that could lead to volume depletion.
Why are lipase and amylase included?
Lipase and amylase are pancreatic enzymes. They are included to provide pancreas-related context when GLP-1 medication use, abdominal symptoms, or provider concerns are present.
Why are liver and bile-flow markers included?
Liver and bile-flow markers are included because GLP-1 medication use and weight loss may overlap with gallbladder, bile-flow, and liver health discussions. FDA labeling for GLP-1 medications includes warnings related to acute gallbladder disease.
Why is prealbumin included?
Prealbumin is included because reduced appetite, rapid weight loss, low protein intake, or restricted eating may affect protein nutrition status during GLP-1 therapy.
Does this panel prove my GLP-1 medication is safe?
No. No lab panel can prove a medication is safe in every situation. This panel helps evaluate selected safety markers that may be useful to review with a licensed healthcare provider.
Important Note
This panel is designed to help evaluate selected biomarkers that may be related to GLP-1 medication safety, kidney function, liver function, pancreatic enzymes, blood sugar, insulin, cholesterol, inflammation, iron status, magnesium, vitamin D, vitamin B12 and folate status, thyroid markers, omega fatty acid status, protein nutrition, urine health, and metabolic wellness. It is not intended to diagnose, treat, cure, or prevent disease by itself. Results should be reviewed with a licensed healthcare provider.